Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Time Interval Between Mifepristone and Misoprostol for Early Pregnancy Loss
NCT07506512Phase 3Not yet recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2027
- Primary completion
- Jul 2031
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of mifepristone, misoprostol in early pregnancy loss (EPL), sponsored by University of Pennsylvania. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
mifepristonemisoprostol
03
Conditions
early pregnancy loss (EPL)
Beyond the preview
Go deeper on NCT07506512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506512.